The randomized phase III Iressa Pan-ASia Study ( IPASS ; ClinicalTrials.gov identifier NCT@ ) of first-line gefitinib versus chemotherapy analyzed samples meeting preplanned specifications ( n = @ evaluable for EGFR mutation ; n = @ mutation-positive ) .